Risk factors for the development of pneumonia in schizophrenia patients infected with COVID-19

Risk factors for the development of pneumonia in schizophrenia patients infected with COVID-19 - Risk factors for the development of pneumonia in schizophrenia patients infected with COVID-19

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050188

Enrollment

100

Registered

2023-02-01

Start date

2023-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia patient infected with COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with schizophrenia and schizoaffective disorder (DSM-5) admitted to Kurita Hospital who were infected with COVID-19 in 2022.

Exclusion criteria

Exclusion criteria: Patients with comorbidities of malignancy, cerebrovascular disease, cardiovascular disease, chronic kidney disease, and epilepsy

Design outcomes

Primary

Measure	Time frame
Association between psychotropic medication (antipsychotics, benzodiazepines, mood stabilizers) taken during COVID-19 infection and development of pneumonia	—

Countries

Japan

Contacts

Public ContactYusuke Arai

Kurita hospital Department of Psychiatry

soundofdistiny@icloud.com026-226-1311

Outcome results